India’s ‘Covaxin’ vaccine on Covid-19 successful in animal trial

Hyderabad (Telangana) – Hyderabad based Bharat Biotech and Indian Council of Medical Research (ICMR) together developed a vaccine on Covid-19 in India. Currently this vaccine is being tested for human responses in various 12 institutes across India. Results of the animal trial showed protective efficiency.

ETHealthworld | Animal study proved Covid vaccine's efficacy: Bharat Biotech #Vaccine #Covaxin #AnimalTrials #AnimalTesting #BharatBiotech https://t.co/CXfyVXWkG8

— ETHealthWorld (@ETHealthWorld) September 12, 2020

• For this trial 20 monkeys (rhesus macaques) were divided into 4 groups of 5. They were given the vaccine in 2 doses. A group of monkeys was administered with placebo while three groups were immunised with three different vaccines and then second dose after 14 days.
• All the monkeys were exposed to the virus 14 days after the second dose. The results showed protective efficiency in them. Antibodies against Covid-19 virus were successfully generated. This showed no replication of the virus in the nasal cavity, throat, and lung tissues of the monkeys.
• No evidence of pneumonia was observed by pathological examination in vaccinated groups. Adverse events were not seen in animals immunised with a two-dose vaccination regimen.

The success of this phase of trial of the vaccine is that the animals vaccinated with ‘Covaxin’ developed robust immune system against Covid-19.